Article By:
Ari Zoldan
Thursday, September 21, 2023 2:15 PM EDT
Extensive research on NDDs has uncovered a different treatment pathway that's enabling some biotechnology firms to target more than one NDD with the same drug candidate.
Biotech Losers In 2021 That Could Bounce Big In The Second Half
$ATHA dropped price on allegations that ceo cheated on a research paper back 10 years ago. Interim ceo said leen kawas research from then had nothing to do with the current drug they are making. All the value here on atha is still in tact.
Biotech Losers In 2021 That Could Bounce Big In The Second Half
$ATHA will crush it!